HUE053949T2 - N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok - Google Patents

N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Info

Publication number
HUE053949T2
HUE053949T2 HUE10739701A HUE10739701A HUE053949T2 HU E053949 T2 HUE053949 T2 HU E053949T2 HU E10739701 A HUE10739701 A HU E10739701A HU E10739701 A HUE10739701 A HU E10739701A HU E053949 T2 HUE053949 T2 HU E053949T2
Authority
HU
Hungary
Prior art keywords
protofibrils
oligomers
terminally truncated
antibodies selective
truncated amyloid
Prior art date
Application number
HUE10739701A
Other languages
English (en)
Hungarian (hu)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda Soederberg
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of HUE053949T2 publication Critical patent/HUE053949T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE10739701A 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok HUE053949T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29

Publications (1)

Publication Number Publication Date
HUE053949T2 true HUE053949T2 (hu) 2021-08-30

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10739701A HUE053949T2 (hu) 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Country Status (16)

Country Link
US (2) US20120100129A1 (2)
EP (2) EP3892633A1 (2)
JP (3) JP2012532094A (2)
AU (1) AU2010267640B2 (2)
CA (1) CA2765602C (2)
CY (1) CY1124034T1 (2)
DK (1) DK2448968T3 (2)
ES (1) ES2864049T3 (2)
HR (1) HRP20210611T1 (2)
HU (1) HUE053949T2 (2)
LT (1) LT2448968T (2)
PL (1) PL2448968T3 (2)
PT (1) PT2448968T (2)
SI (1) SI2448968T1 (2)
SM (1) SMT202100237T1 (2)
WO (1) WO2011001366A1 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
BR112013023211B1 (pt) 2011-03-16 2022-11-08 Vivoryon Therapeutics N.V. Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
RU2019102746A (ru) 2016-07-14 2020-08-14 Биоарктик Аб Белок для транспорта в мозг
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
MX2021000778A (es) 2018-07-24 2021-03-31 Eisai R&D Man Co Ltd Metodos de tratamiento y prevencion de la enfermedad de alzheimer.
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
US20220251518A1 (en) * 2019-07-08 2022-08-11 Terumo Kabushik Kaisha Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
RS66984B1 (sr) 2020-06-26 2025-07-31 Bioarctic Ab Antitela koja vezuju alfa-sinuklein protofibril
EP4367516A1 (en) 2021-07-09 2024-05-15 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
US20240352109A1 (en) 2021-08-30 2024-10-24 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
MX2024009492A (es) 2022-02-02 2024-08-09 Eisai R&D Man Co Ltd Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181).
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ATE283285T1 (de) * 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
EP1309341A2 (en) * 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
KR100891620B1 (ko) * 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
BRPI0513959A (pt) * 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
DK2207568T3 (en) * 2007-11-16 2017-09-18 Univ Rockefeller ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína

Also Published As

Publication number Publication date
US20120100129A1 (en) 2012-04-26
JP6884025B2 (ja) 2021-06-09
CY1124034T1 (el) 2022-05-27
EP2448968B1 (en) 2021-01-27
CA2765602C (en) 2021-05-25
JP2019218362A (ja) 2019-12-26
JP2012532094A (ja) 2012-12-13
SI2448968T1 (sl) 2021-07-30
US20230295283A1 (en) 2023-09-21
JP2017197531A (ja) 2017-11-02
WO2011001366A1 (en) 2011-01-06
HRP20210611T1 (hr) 2021-05-28
CA2765602A1 (en) 2011-01-06
EP2448968A1 (en) 2012-05-09
AU2010267640B2 (en) 2015-03-05
ES2864049T3 (es) 2021-10-13
LT2448968T (lt) 2021-05-10
PL2448968T3 (pl) 2021-09-13
SMT202100237T1 (it) 2021-05-07
EP3892633A1 (en) 2021-10-13
AU2010267640A1 (en) 2012-01-19
DK2448968T3 (da) 2021-04-12
PT2448968T (pt) 2021-04-30

Similar Documents

Publication Publication Date Title
HUE053949T2 (hu) N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok
PT2406284T (pt) Anticorpos anti-bcma
PT2406399T (pt) Proteínas mirac
DOS2010000009S (es) Botella
DK2480734T3 (da) Skinnesystem
DOS2010000006S (es) Botella
EP2448809A4 (en) CHANNEL SYSTEM
UY3958Q (es) Botella
BRPI1008979A2 (pt) meio de fixação
ITPD20090053U1 (it) Paradordi per banchine
ES1071736Y (es) Botella
DE112010001522A5 (de) Mobile förderbrücke
DE112010001392A5 (de) Vibrator
ITCT20090003U1 (it) Telepass -2 per non udenti
TH93312B (th) ขวด
FR2951765B1 (fr) Paumelle pour persiennes
FI20090460A0 (fi) Määritysmenetelmä
FI20090461A0 (fi) Määritysmenetelmä
FI20096331A0 (fi) Antibodin käyttö
DOS2009000212S (es) Botella
DOS2009000147S (es) Botella
CR10687S (es) Viga bloque
TH93146B (th) ขวด
CN301360184S (zh) 瓶
UA19173S (uk) Пляшка